Hong Kong Equities Navigate Cross-Border Headwinds as Tech and Biotech Diverge in 2026Global Report·Sep 1 at 11:33 AM02635+2.20%06660+1.63%
AIM Vaccine Seeks Approval for High-Potency Human Diploid Cell Rabies ShotTip Ranks·Aug 24 at 12:14 AM06660+1.63%
AIM Vaccine files NMPA registration for high-potency human diploid rabies vaccinePUBT·Aug 24 at 12:02 AM06660+1.63%
AIM Vaccine Advances Serum-Free Rabies Shot Toward China Market ApprovalTip Ranks·Aug 3 at 12:09 AM06660+1.63%
AIM Vaccine submits additional NMPA data for serum-free rabies vaccine after Phase III trial unblindingPUBT·Aug 3 at 12:00 AM06660+1.63%
Hong Kong Capital Flows Signal a Shift: What Mining Surges and Solar Struggles MeanGlobal Report·Jul 21 at 09:25 AM01258+0.06%06808+0.95%
"Performance" AIM VACCINE's losses widened to 675 million yuan last yearAASTOCKS·Mar 31 at 02:08 AM159849-0.99%159316+0.42%
AIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue DeclineTip Ranks·Mar 30 at 04:24 PM512290-0.58%520880+0.86%
AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share IssuanceTip Ranks·Mar 30 at 04:13 PM159102-0.36%5606000.00%
